
Relugolix-d₆

Cat. No.:	HY-16474S	
Molecular Formula:	$C_{29}H_{21}D_6F_2N_7O_5S$	
Molecular Weight:	629.67	
Target:	GnRH Receptor; Isotope-Labeled Compounds	
Pathway:	GPCR/G Protein; Others	
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.	Ū



REFERENCES

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

[2]. Daisuke Nakata, et al. Suppression of the hypothalamic-pituitary-gonadal axis by TAK-385 (relugolix), a novel, investigational, orally active, small molecule gonadotropin-releasing hormone (GnRH) antagonist: studies in human GnRH receptor knock-in mice. Eur J Pharmacol. 2014 Jan 15;723:167-74.

[3]. Kazuhiro Miwa, et al. Discovery of 1-{4-[1-(2,6-Difluorobenzyl)-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl]phenyl]-3-methoxyurea (TAK-385) as a Potent, Orally Active, Non-Peptide Antagonist of the Human Gonadotropin-Releasing Hormone Receptor. doi/10.1021/jm200216q


Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Dest Park Dr. Suite O. Manmauth. Junction: NL 09952, USA

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA





Product Data Sheet